HRP20040587B1 - Injekcijska otopina jednog lhrh antagonista - Google Patents
Injekcijska otopina jednog lhrh antagonistaInfo
- Publication number
- HRP20040587B1 HRP20040587B1 HR20040587A HRP20040587A HRP20040587B1 HR P20040587 B1 HRP20040587 B1 HR P20040587B1 HR 20040587 A HR20040587 A HR 20040587A HR P20040587 A HRP20040587 A HR P20040587A HR P20040587 B1 HRP20040587 B1 HR P20040587B1
- Authority
- HR
- Croatia
- Prior art keywords
- lhrh antagonist
- gluconic acid
- injection solution
- adjuvant
- surfactant
- Prior art date
Links
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title abstract 4
- 239000002474 gonadorelin antagonist Substances 0.000 title abstract 4
- 238000002347 injection Methods 0.000 title 1
- 239000007924 injection Substances 0.000 title 1
- 239000000243 solution Substances 0.000 title 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 abstract 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 abstract 4
- 235000012208 gluconic acid Nutrition 0.000 abstract 4
- 239000000174 gluconic acid Substances 0.000 abstract 4
- 239000002671 adjuvant Substances 0.000 abstract 2
- 239000004094 surface-active agent Substances 0.000 abstract 2
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 abstract 1
- KATZUZNTRINHDT-HALMFYTRSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino Chemical compound C([C@@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KATZUZNTRINHDT-HALMFYTRSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 108010023617 abarelix Proteins 0.000 abstract 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 abstract 1
- 229960002184 abarelix Drugs 0.000 abstract 1
- 108010070670 antarelix Proteins 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 229940127233 azaline B Drugs 0.000 abstract 1
- 108700008462 cetrorelix Proteins 0.000 abstract 1
- 229960003230 cetrorelix Drugs 0.000 abstract 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 abstract 1
- 125000000422 delta-lactone group Chemical group 0.000 abstract 1
- 108700032141 ganirelix Proteins 0.000 abstract 1
- 229960003794 ganirelix Drugs 0.000 abstract 1
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 abstract 1
- QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 abstract 1
- 108010083551 iturelix Proteins 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 229950011372 teverelix Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Vodena otopina za uštrcavanje LHRH antagonista koja sadrži glukonsku kiselinu, po izboru surfaktanti pomoćno sredstvo, naznačena time, da se kao LHRH antagonist koriste cetrorelix, teverelix, D-63 153 (Ac-D-Nal-pCl-D-Phe-3-D-Pal-Ser-N-Me-Tyr-D-H-Cit-Iso-Leu-Arg-Pro-D-Ala-NH2), ganirelix, abarelix,antide ili azaline B i da je glukonska kiselina nazočna u iznosu koji je veći od ekvimolarnog, temeljeno na količini LHRH antagonista, da se glukonska kiselina dodaje u obliku glukonska kiselina delta-lakton, te da se po izboru Tween 80 rabi kao surfaktant, a mannitol kao pomoćno sredstvo. Patent sadrži još 4 patentna zahtjeva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10157628A DE10157628A1 (de) | 2001-11-26 | 2001-11-26 | Injektionslösung eines LHRH-Antagonisten |
| PCT/EP2002/012798 WO2003045419A1 (de) | 2001-11-26 | 2002-11-15 | Injektionslösung eines lhrh-antagonisten |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20040587A2 HRP20040587A2 (en) | 2004-10-31 |
| HRP20040587B1 true HRP20040587B1 (hr) | 2008-01-31 |
Family
ID=7706799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20040587A HRP20040587B1 (hr) | 2001-11-26 | 2004-06-24 | Injekcijska otopina jednog lhrh antagonista |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1448221B1 (hr) |
| JP (1) | JP4343693B2 (hr) |
| KR (1) | KR100936636B1 (hr) |
| CN (1) | CN100404068C (hr) |
| AR (1) | AR037424A1 (hr) |
| AT (1) | ATE350050T1 (hr) |
| AU (1) | AU2002365504B2 (hr) |
| BR (1) | BRPI0214412B8 (hr) |
| CO (1) | CO5580793A2 (hr) |
| CY (1) | CY1106401T1 (hr) |
| DE (2) | DE10157628A1 (hr) |
| DK (1) | DK1448221T3 (hr) |
| EA (1) | EA010787B1 (hr) |
| ES (1) | ES2276970T3 (hr) |
| GE (1) | GEP20063861B (hr) |
| HK (1) | HK1073078A1 (hr) |
| HR (1) | HRP20040587B1 (hr) |
| HU (1) | HU230992B1 (hr) |
| IL (2) | IL161894A0 (hr) |
| IS (1) | IS2725B (hr) |
| ME (1) | ME00499B (hr) |
| MX (1) | MXPA04005018A (hr) |
| NO (1) | NO333364B1 (hr) |
| NZ (1) | NZ533712A (hr) |
| PL (1) | PL206199B1 (hr) |
| PT (1) | PT1448221E (hr) |
| RS (1) | RS51408B (hr) |
| RU (1) | RU2322969C2 (hr) |
| SI (1) | SI1448221T1 (hr) |
| TW (1) | TWI312283B (hr) |
| UA (1) | UA81612C2 (hr) |
| WO (1) | WO2003045419A1 (hr) |
| ZA (1) | ZA200404051B (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8119159B2 (en) | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| JP5450052B2 (ja) | 2006-04-07 | 2014-03-26 | メリオン リサーチ Ｉｉｉ リミテッド | 強化剤を含む固体経口投与剤形 |
| US8999383B2 (en) * | 2008-05-07 | 2015-04-07 | Merrion Research Iii Limited | Compositions of GnRH related compounds and processes of preparation |
| WO2011120033A1 (en) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| JP2014501784A (ja) | 2011-01-07 | 2014-01-23 | メリオン・リサーチ・Ｉｉｉ・リミテッド | 経口投与用の鉄の医薬組成物 |
| CN103690560B (zh) * | 2013-12-17 | 2016-08-17 | 辽宁海思科制药有限公司 | 一种转化糖电解质注射液药物组合物及其制备方法 |
| WO2016120378A1 (en) | 2015-01-29 | 2016-08-04 | Novo Nordisk A/S | Tablets comprising glp-1 agonist and enteric coating |
| RU2614234C2 (ru) * | 2015-03-31 | 2017-03-23 | Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН) | Фармацевтическая композиция на основе 3-(4-Метилимидазол-1-ил)имидазо[1,2-b][1,2,4,5]тетразина в качестве противоопухолевого средства |
| EP3573663B1 (en) * | 2017-01-30 | 2021-04-07 | Antev Limited | A composition comprising at least one gnrh antagonist |
| PL3811927T3 (pl) | 2019-10-24 | 2022-02-07 | Sun Pharmaceutical Industries Ltd | Trwała pozajelitowa postać dawkowania octanu cetroreliksu |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001021194A2 (en) * | 1999-09-23 | 2001-03-29 | Zentaris Ag | Method for the therapeutic management of endometriosis and fallopian tube obstruction |
| WO2001087265A2 (de) * | 2000-05-18 | 2001-11-22 | Zentaris Ag | Pharmazeutische darreichungsform für peptide, verfahren zu deren herstellung und verwendung |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4800191A (en) * | 1987-07-17 | 1989-01-24 | Schally Andrew Victor | LHRH antagonists |
| US5300492A (en) * | 1988-02-10 | 1994-04-05 | Tap Pharmaceuticals | LHRH analogs |
| US5140009A (en) * | 1988-02-10 | 1992-08-18 | Tap Pharmaceuticals, Inc. | Octapeptide LHRH antagonists |
-
2001
- 2001-11-26 DE DE10157628A patent/DE10157628A1/de not_active Withdrawn
-
2002
- 2002-11-15 CN CNB028234901A patent/CN100404068C/zh not_active Expired - Lifetime
- 2002-11-15 NZ NZ533712A patent/NZ533712A/en not_active IP Right Cessation
- 2002-11-15 MX MXPA04005018A patent/MXPA04005018A/es active IP Right Grant
- 2002-11-15 AT AT02790384T patent/ATE350050T1/de active
- 2002-11-15 UA UA20040503816A patent/UA81612C2/ru unknown
- 2002-11-15 DE DE50209193T patent/DE50209193D1/de not_active Expired - Lifetime
- 2002-11-15 ES ES02790384T patent/ES2276970T3/es not_active Expired - Lifetime
- 2002-11-15 PT PT02790384T patent/PT1448221E/pt unknown
- 2002-11-15 KR KR1020047007807A patent/KR100936636B1/ko active IP Right Grant
- 2002-11-15 ME MEP-2008-800A patent/ME00499B/me unknown
- 2002-11-15 RU RU2004119821/15A patent/RU2322969C2/ru active
- 2002-11-15 PL PL369548A patent/PL206199B1/pl unknown
- 2002-11-15 AU AU2002365504A patent/AU2002365504B2/en not_active Expired
- 2002-11-15 SI SI200230505T patent/SI1448221T1/sl unknown
- 2002-11-15 WO PCT/EP2002/012798 patent/WO2003045419A1/de active IP Right Grant
- 2002-11-15 HU HU0401986A patent/HU230992B1/hu unknown
- 2002-11-15 BR BRPI0214412A patent/BRPI0214412B8/pt not_active IP Right Cessation
- 2002-11-15 IL IL16189402A patent/IL161894A0/xx unknown
- 2002-11-15 GE GE5568A patent/GEP20063861B/en unknown
- 2002-11-15 EA EA200400742A patent/EA010787B1/ru unknown
- 2002-11-15 RS YUP-449/04A patent/RS51408B/sr unknown
- 2002-11-15 DK DK02790384T patent/DK1448221T3/da active
- 2002-11-15 EP EP02790384A patent/EP1448221B1/de not_active Expired - Lifetime
- 2002-11-15 JP JP2003546920A patent/JP4343693B2/ja not_active Expired - Lifetime
- 2002-11-20 TW TW091133846A patent/TWI312283B/zh not_active IP Right Cessation
- 2002-11-25 AR ARP020104523A patent/AR037424A1/es not_active Application Discontinuation
-
2004
- 2004-05-06 IS IS7251A patent/IS2725B/is unknown
- 2004-05-10 IL IL161894A patent/IL161894A/en active IP Right Grant
- 2004-05-14 CO CO04044748A patent/CO5580793A2/es not_active Application Discontinuation
- 2004-05-25 ZA ZA2004/04051A patent/ZA200404051B/en unknown
- 2004-06-11 NO NO20042449A patent/NO333364B1/no not_active IP Right Cessation
- 2004-06-24 HR HR20040587A patent/HRP20040587B1/hr not_active IP Right Cessation
-
2005
- 2005-07-11 HK HK05105809.5A patent/HK1073078A1/xx not_active IP Right Cessation
-
2007
- 2007-03-20 CY CY20071100391T patent/CY1106401T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001021194A2 (en) * | 1999-09-23 | 2001-03-29 | Zentaris Ag | Method for the therapeutic management of endometriosis and fallopian tube obstruction |
| WO2001087265A2 (de) * | 2000-05-18 | 2001-11-22 | Zentaris Ag | Pharmazeutische darreichungsform für peptide, verfahren zu deren herstellung und verwendung |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20040587B1 (hr) | Injekcijska otopina jednog lhrh antagonista | |
| AR033059A1 (es) | Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada. | |
| MEP28708A (en) | Acidic insulin preparations with improved stability | |
| DOP2001000197A (es) | Interleuquina-2 estabilizada | |
| PE84899A1 (es) | Formulaciones farmaceuticas que contienen voriconazol | |
| TR200302105T4 (tr) | Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları. | |
| HRP20000181B1 (en) | 2-methyl-thieno-benzodiazepine formulation | |
| CA2459309A1 (en) | Sustained release of microcrystalline peptide suspensions | |
| ATE287705T1 (de) | Wärmegellierende bioabbaubare wässrige polymerlösung | |
| CO5540325A2 (es) | Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados | |
| CO5400118A1 (es) | Composiciones detergentes humectantes | |
| TW200628071A (en) | Active compound combinations having insecticidal and acaricidal properties | |
| CO5540368A2 (es) | Composicion de liberacion sostenida y proceso para producirla | |
| CA2412759A1 (en) | Injectable solution of an lhrh antagonist | |
| RS50504B (sr) | Tečne formulacije | |
| DE602004015725D1 (de) | Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors | |
| BR0304298A (pt) | Composição contendo um ácido orgânico cosmeticamente ativo e um produto de legume | |
| BR0313257A (pt) | Composição pesticida granulada | |
| HRP20010238B1 (en) | 2-methyl-thieno-benzodiazepine formulation | |
| IL155788A (en) | A highly purified ifn – β active and mannitol-containing preparation, a method to make an improved stability of ifn – β active, and a method to enhance the stability of ifn – β in biologically active formulation. | |
| DK0832107T3 (da) | Forbedret peptid, immunogen sammensætning og vaccine eller medicinsk præparat, fremgangsmåde til immunisering af dyr mod hormonet LHRH samt analoge af LHRH-tandempeptid-gentagelsespeptidet og deres andvendelse som vaccine | |
| ES2119405T3 (es) | Composiciones de detergentes. | |
| CO5540279A2 (es) | Formulacion liofilitada de 2-metil-tieno-benzodiazepina | |
| DE50102625D1 (de) | Verbindungen zur Bestimmung der Aktivität von Phospholipase A2 | |
| RU2003107560A (ru) | Соль пептида (варианты), способ ее получения и применение, фармацевтическая композиция и способ ее получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| PNAN | Change of the applicant name, address/residence |
Owner name: ZENTARIS GMBH, DE |
|
| B1PR | Patent granted | ||
| PNAN | Change of the applicant name, address/residence |
Owner name: AETERNA ZENTARIS GMBH, DE |
|
| PPPP | Transfer of rights |
Owner name: ZENTARIS IVF GMBH, DE |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20181108 Year of fee payment: 17 |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20191024 Year of fee payment: 18 |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20201110 Year of fee payment: 19 |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20211111 Year of fee payment: 20 |
|
| PB20 | Patent expired after termination of 20 years |
Effective date: 20221115 |